Positive Phase 1 results for the company's epilepsy drug candidate are coupled with a significant financing deal that could dilute shares.
The networking specialist saw trading volume spike more than 50 times its daily average following the announcement.
Tecentriq in combination with Zepzelca approved as a first-line maintenance treatment for extensive-stage small cell lung cancer, a significant advancement for a hard-to-treat cancer.
Sale was executed under a pre-planned 10b5-1 trading arrangement as the AI chipmaker's valuation continues to soar.
Disruption at a key California facility could tighten fuel markets, boosting margins for competing refiners in an already vulnerable region.
The industrial laser firm's strategic pivot into the electronic warfare and operational resilience markets is fueled by a new capital raise and key acquisitions.
The $0.3 million deal with a major Southern European telecom carrier boosts the network solutions provider's shares in after-hours trading.
Company transfers equity stake in a strategic deal for future capital rights, resolving outstanding brand disputes and boosting investor confidence.